The purpose of this study was to clarify the protective role of mangiferin on postinfarction myocardial remodeling and potential mechanisms. The myocardial infarction (MI) model was established by ligating the left anterior descending coronary artery. Cardiac function, myocardial apoptosis and fibrosis, serum tumor necrosis factor-α (TNF-α) and phosphorylated p38 mitogen-activated protein kinase (MAPK) were examined by echocardiography, histological staining, ELISA and Western blot, respectively. Mangiferin attenuated MI and prevented the development of intercellular fibrosis. Western blotting underscores that the p38 MAPK cascade plays an important role in the cardioprotective effect of mangiferin during MI. Inhibition of p38 MAPK significantly decreased serum TNF-α levels. Transferase-mediated uridine nick end labeling and Masson staining also showed that mangiferin reduced apoptosis and fibrosis in myocardium remodeling. Based on these results, we conclude that mangiferin has a therapeutic effect on post-MI left ventricular remodeling and improves cardiac function.

Keywords:
Mangiferin, p38 mitogen-activated protein kinase, Myocardial infarction, Left ventricular remodeling
This content is only available via PDF.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.